Amyotrophic Lateral Sclerosis Treatment Market Sales to Reach US$ 1021 Million in 2032 | CAGR of 5.6%

Investment in research and development by pharmaceutical companies is expected to propel the growth of the ALS market as they work to develop new treatments for the disease.

New York City, New York, UNITED STATES

New York, April 14, 2023 (GLOBE NEWSWIRE) -- The global Amyotrophic Lateral Sclerosis Treatment Market was valued at US$ 600 million in 2022 and is expected to grow US$ 1021 million in 2032. Between 2023 and 2032, this market is estimated to register a CAGR of 5.6%. The market for pharmaceutical medications, medical equipment, and other therapies used to treat ALS, a deadly neurological condition that affects nerve cells in the brain and spinal cord, is referred to as the global amyotrophic lateral sclerosis treatment market. Motor neurons, which govern muscular movement, degenerate and die as a result of ALS, causing muscle weakening, paralysis, and ultimately respiratory failure. The ALS treatment market includes medical devices like ventilators, feeding tubes, & mobility aids that are used to support ALS patients as the disease advances, as well as FDA-approved medications like Riluzole & Edaravone, which are used to reduce the disease's progression.

global Amyotrophic Lateral Sclerosis Treatment Market growth

Get a holistic overview of amyotrophic lateral sclerosis treatment market by industry experts to evaluate and develop growth strategies. Download the Sample -

Key Takeaway:

  • By type, in 2022, the Amyotrophic Lateral Sclerosis Treatment Market was dominated by the Sporadic ALS segment due to its increased usage.
  • By drug, the Riluzole segment is estimated to be the most lucrative segment in the Global Amyotrophic Lateral Sclerosis market
  • By Treatment, the medication holds the largest revenue share of 22% and a projected CAGR of 5.59% during the forecast period.
  • By end-user, the hospitals segment dominated the largest market share in end-user type analysis
  • In 2022, North America dominated the market with the highest revenue share of 31%.
  • APAC is anticipated to have the highest CAGR among all the regions.
  • APAC is expected to grow at a greater pace owing to affordable prices, increasing medical tourism, as well as hospitals and clinics, among other factors.

Factors Affecting the Growth of the Amyotrophic Lateral Sclerosis Treatment Market?

The growth of the ALS treatment market is influenced by several factors, including:

  • Increasing prevalence of ALS: The prevalence of ALS is increasing globally, which is expected to drive the demand for ALS treatments.
  • Advancements in technology: Advancements in technology have led to the development of new treatment options, such as gene therapy, stem cell therapy, and RNA interference therapy, which are expected to drive market growth.
  • Growing awareness and diagnosis: The growing awareness of ALS and better diagnosis of the disease are also expected to drive market growth.
  • Increasing investment in research and development: Pharmaceutical companies are investing heavily in research and development to develop new treatments for ALS, which is expected to drive market growth.
  • Favourable regulatory environment: The regulatory environment for ALS treatments is favourable, which is expected to encourage the development of new treatments and drive market growth.

if you need a more focused analysis of a particular region or segment, our analysts can customize the report to meet your specific requirements. Feel free to contact us for further assistance @

Market Growth

The Amyotrophic Lateral Sclerosis (ALS) treatment market is expected to experience steady growth in the coming years. ALS is a rare disease, but its prevalence is increasing globally, which is driving the demand for ALS treatments. Advances in technology have led to the development of new treatment options for ALS, which is expected to drive market growth. Growing awareness of ALS and better diagnosis of the disease are also driving the market growth. The pharmaceutical industry is investing heavily in research and development to develop new treatments for ALS, which is driving market growth. The regulatory environment for ALS treatments is favourable, which is encouraging the development of new treatments and driving the market growth. Increasing healthcare expenditure, particularly in developing countries, is driving market growth as well.

Regional Analysis

The North American market for ALS treatment market is expected to be the most lucrative, both in terms of revenue and market share, during the period 2022-2032. North America held the largest revenue share in 2022, accounting for around 31% of the global market. This is due to factors such as the high incidence of ALS in North America, favourable reimbursement policies, and the presence of well-established healthcare infrastructure. Europe is the second-largest market for ALS treatments, driven by the high prevalence of ALS in some European countries and the presence of a well-established healthcare infrastructure. Meanwhile, the Asia Pacific region is expected to experience significant growth in the ALS market due to increasing awareness of ALS and improving healthcare infrastructure.

To know about the regional trends and drivers that will have an impact on the market - Request a sample report!

Scope of the Report

Report AttributeDetails
Market Value (2022)USD 600 million
Market Size (2032)USD 1021 million
CAGR (from 2022 to 2032)5.6%
North America Revenue Share31%
Historic Period2016 to 2022
Base Year2022
Forecast Year2023 to 2032

Market Drivers

With ALS being an uncommon disease, its frequency and incidence have been rising over time. In the United States, 5,000 people are given an ALS diagnosis each year, according to the ALS Association. The number of ALS sufferers is anticipated to increase as the population ages, fueling demand for ALS medicines and treatments. Recent improvements in R&D., particularly in the fields of medication discovery and gene therapy, have benefited the ALS market. These developments are anticipated to result in the creation of fresh, more potent therapies for ALS patients.

Market Restraints

There is currently no cure for ALS, as well as the medicines that are available only serve to control the symptoms and reduce the disease's progression. This restricts patient options and could lower the overall need for ALS medicines and treatments. The cost of ALS medications and treatments can be high, especially for people who need continuous care. This may restrict a patient's access to care, especially in low- and middle-income nations.

Market Opportunities

There is still a sizable market opportunity for the creation of fresh, more efficient treatments for ALS patients. There are current studies in fields including immunotherapy, stem cell therapy, or gene therapy that may result in novel treatment choices for ALS patients. Patients with ALS, especially those who are unable to travel to specialized ALS clinics, may benefit from more efficient and accessible care thanks to the use of telemedicine & digital health platforms. These systems can enhance data collecting and processing, which can hasten the creation of novel ALS treatments.

Immediate Delivery Available | Buy This Premium Research Report@

Report Segmentation of the Amyotrophic Lateral Sclerosis Treatment Market

Type Insight

In terms of type and segment of amyotrophic lateral sclerosis treatments, sporadic ALS retains the biggest market share in 2022 (86.35%).The market for treatments for amyotrophic lateral sclerosis is divided into two types, familial ALS and sporadic ALS. This section discusses the equipment needed to help ALS patients as their condition worsens, such as feeding tubes, ventilators, and mobility aids. These tools can enhance the quality of life for ALS patients and help maintain respiratory balance and prevent malnutrition. The market for ALS treatments is extremely competitive, and numerous businesses and research institutions are attempting to create novel medications and medical equipment to treat ALS.

 Drug Type Insight

According to estimates, the segment selling riluzole will be the most lucrative one in the market for amyotrophic lateral sclerosis worldwide. The market is further segmented by drug type into Riluzole, Edaravone, and Nuedexta. However, a number of different medications are being researched and tested to treat ALS. In 2022, the segment for riluzole is expected to have a market share of 37% as well as a CAGR of 5.6%. Riluzole and Edaravone now enjoy a monopoly on the market, but these medications, which are still in the early stages of development & testing, show promise for the future of ALS treatment.

Treatment  Insight

The market for treatments for amyotrophic lateral sclerosis is predicted to be the most lucrative area. The market is divided into Medication, Respiratory Therapy, Speech Therapy, Physical Therapy, Chemotherapy, and Stem Cell Therapy based on the results of the Treatment Analysis. The medication has the highest revenue share (22%), and its CAGR over the forecast period is expected to be 5.59%. This refers to the administration of medications to treat or control a certain disease or condition.

End User  Insight

The market is divided into hospitals, specialty centres, research & academic institutes, and diagnostic centres based on the end-user. Hospitals are thought to be the most lucrative end-user group in the global market for amyotrophic lateral sclerosis, accounting for 26% of total market revenue and expected to grow at a CAGR of 5.59% over the course of the forecast period. These facilities offer ALS patient diagnosis, care, and management, frequently in conjunction with specialized ALS centres.

If you want to get a better understanding of the report, you can access a PDF sample, which includes the complete table of contents, list of exhibits, selected illustrations, and example pages @

Market Segmentation

Based on Type

  • Sporadic ALS (SALS)
  • Familial ALS (FALS)

Based on Drug Type

  • Riluzole
  • Edaravone
  • Nuedexta

Based on Treatment Type

  • Medication
  • Respiratory Therapy
  • Speech Therapy
  • Physical Therapy
  • Chemotherapy
  • Stem Cell Therapy
  • Other Treatments

  Based on End-User

  • Hospitals
  • Specialty Centres
  • Research and Academic Institutes
  • Diagnostic Centers
  • Other End Users.

By Geography

  • North America
    • The US
    • Canada
    • Mexico
  • Western Europe
    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Portugal
    • Ireland
    • Austria
    • Switzerland
    • Benelux
    • Nordic
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • The Czech Republic
    • Greece
    • Rest of Eastern Europe
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC
  • Latin America
    • Brazil
    • Colombia
    • Chile
    • Argentina
    • Costa Rica
    • Rest of Latin America
  • Middle East & Africa
    • Algeria
    • Egypt
    • Israel
    • Kuwait
    • Nigeria
    • Saudi Arabia
    • South Africa
    • Turkey
    • United Arab Emirates
    • Rest of MEA

Competitive Landscape

The global Amyotrophic Lateral Sclerosis market is a highly competitive market with several key players operating in the market. The market is dominated by a few major players who hold a significant market share. Some of the major players include:

  • Sanofi
  • Mitsubishi Tanabe Pharma Corporation
  • BrainStorm Cell Limited
  • Mylan N.V.
  • Ionis Pharmaceuticals
  • Biogen
  • Covis Pharma
  • Apotex Inc.
  • Ascend Laboratories LLC
  • ITF Pharma
  • Genervon Biopharmaceuticals, LLC
  • Bausch Health Companies Inc.
  • Orion Pharma Ltd.
  • Amylyx Pharmaceuticals Inc
  • Sun Pharmaceutical Industries Ltd.
  • Advanz Pharmaceutical
  • Otsuka Pharmaceutical Co., Ltd.
  • Other Key Players

Recent Development of the Amyotrophic Lateral Sclerosis Treatment Market

  • In August 2021-For the treatment of ALS, Biogen's Tofersen received orphan drug designation from the European Medicines Agency (EMA). Tofersen is an experimental treatment for ALS patients with a specific gene mutation that aims to treat the genetic cause.
  • In May 2021-NeuroSphere, a neurostimulator, has been approved for use in the treatment of ALS by the US Food and Drug Administration (FDA). In patients with ALS, the device is intended to improve muscle control by stimulating nerves in the spinal cord.
  • In March 2021-The HEALEY ALS Platform Trial, which aims to accelerate the development of effective ALS treatments, was launched in collaboration with Biogen, according to the ALS Association's announcement. The preliminary will test different treatments at the same time, determined to distinguish promising medicines all the more rapidly.

Browse More Related Reports:

About Us:

Market.US (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us on LinkedIn | Facebook | Twitter

Our Blog: 


Contact Data